title: Is the treatment of WHO category I tuberculosis with 2HRZE/6HE a defensible practice?
authors.affiliation: University of Alberta, Edmonton, Canada.
authors.forename: R
authors.initials: R
authors.lastname: Long
authors.forename: M
authors.initials: M
authors.lastname: Scalcini
mesh_terms: D000995:Antitubercular Agents / Q000008:administration & dosage*; D003906:Developing Countries; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D004977:Ethambutol / Q000008:administration & dosage; D006801:Humans; D007538:Isoniazid / Q000008:administration & dosage; D009169:Mycobacterium tuberculosis / Q000187:drug effects; D011718:Pyrazinamide / Q000008:administration & dosage; D012293:Rifampin / Q000008:administration & dosage; D013307:Streptomycin / Q000008:administration & dosage; D018088:Tuberculosis, Multidrug-Resistant; D014944:World Health Organization
chemical_list: D000995:Antitubercular Agents; D011718:Pyrazinamide; D004977:Ethambutol; D007538:Isoniazid; D012293:Rifampin; D013307:Streptomycin